The Quiet Squeeze on Specialty Drug Profits
Pharmacy benefit manager reforms that have been building through regulatory pressure and congressional scrutiny are now landing where it hurts most: the specialty drug supply chain, where thin margins are getting thinner and independent pharmacies are starting to feel the structural weight of the new rules.
How PBM Reform Is Reshaping the Drug Pricing Landscape
For years, pharmacy benefit managers operated as largely invisible middlemen between insurers, drug manufacturers, and the pharmacies filling prescriptions. Their power came from controlling formularies, setting reimbursement rates, and extracting rebates from manufacturers that rarely flowed back to patients. That model is now under direct legislative assault. The Inflation Reduction Act opened the door, and a wave of state-level PBM reform laws – passed in more than a dozen states over the past two years – has pushed the pressure further down the chain.
Specialty drugs are where the stakes are highest. These medications, which treat complex conditions like cancer, rheumatoid arthritis, and multiple sclerosis, carry list prices that can run into tens of thousands of dollars per year per patient. The margin that pharmacies earn on specialty drugs has historically made up for the paper-thin reimbursements on generic drugs. Reform efforts targeting spread pricing – the practice of billing payers more than what the pharmacy is reimbursed – are now compressing what was once a reliable profit buffer. When spread pricing gets regulated or banned outright, the economics that made specialty drugs a financial lifeline for many pharmacies start to unravel.
The pass-through pricing mandates now active in several states require PBMs to reimburse pharmacies at the same rate they charge plan sponsors, eliminating the spread entirely for covered prescriptions. For hospital-affiliated and large chain pharmacies, the adjustment is painful but manageable. For independent specialty pharmacies operating with smaller patient volumes and higher overhead per prescription, the margin compression can be existential. Some have already begun exiting certain specialty drug categories rather than fill prescriptions at a loss.
Rebate reform adds another layer of complexity. Historically, drug manufacturers paid PBMs substantial rebates in exchange for preferred placement on formularies. Proposals to require those rebates to be passed directly to patients at the point of sale would reduce the revenue PBMs receive from manufacturers – and PBMs are already signaling that they will offset that reduction by cutting pharmacy reimbursement rates further. The math is circular and punishing: every dollar of reform at one end of the chain tends to find a new place to pinch at the other.
Specialty Pharmacies Caught in the Crossfire
Specialty pharmacies do not operate like retail drug stores. They provide clinical support services, coordinate prior authorizations, manage cold-chain logistics for biologics, and maintain patient adherence programs that reduce hospitalizations. None of that infrastructure is free, and most of it is not separately reimbursed by PBMs. When reimbursement on the drug itself compresses, there is no secondary revenue stream to absorb the loss. The clinical work gets subsidized by the drug margin, or it does not get done at all.
The limited distribution network model that governs many high-cost specialty drugs creates an additional pressure point. Manufacturers grant exclusive dispensing rights for certain drugs – particularly newer biologics and gene therapies – to a small number of specialty pharmacies, often PBM-owned ones. Independent pharmacies locked out of those networks cannot compete for the highest-margin prescriptions regardless of their service quality. As PBMs face pressure to unbundle their pharmacy businesses from their adjudication businesses, there is a real question about whether that vertical integration will be addressed or simply rearranged.
White-collar layoffs spreading across the healthcare sector are compounding the staffing cost problem. Specialty pharmacies that scaled up clinical teams during the biosimilar boom of the past few years are now facing headcount pressure at exactly the moment when patient complexity is increasing. A rise in severance costs across the broader economy is hitting pharmacy operations teams that have already been trimmed.
Biosimilar uptake, which was supposed to relieve pricing pressure on the specialty side, has had mixed results. For drugs like adalimumab – the active ingredient in Humira – the arrival of biosimilar competitors drove list prices down dramatically, but PBM formulary decisions initially favored the branded product because it generated higher rebates. The formulary games that reform was meant to clean up persisted even as biosimilar options multiplied. Only now, with more aggressive formulary switching under pressure from plan sponsors, are biosimilars gaining meaningful market share, and the lower price points are once again compressing dispensing margins for specialty pharmacies filling those prescriptions.
There is also a geographic dimension that rarely gets discussed in the policy debate. Specialty pharmacy access is heavily concentrated in urban and suburban markets. Rural patients with complex chronic conditions frequently rely on mail-order dispensing through PBM-owned pharmacies, which are better positioned to absorb margin compression because of their scale. If independent specialty pharmacies in mid-sized and smaller markets continue to exit categories or close entirely, the de facto result is a further consolidation of specialty drug dispensing into the very PBM-owned channels that reform was meant to check.
What Comes Next for Drug Margins
Federal PBM reform legislation has stalled repeatedly in Congress, caught between competing lobbying interests and a broader political environment where healthcare pricing is contested terrain. The state-level action continues to fill the gap, but state laws vary enough in their scope and enforcement mechanisms that compliance costs for national PBMs are manageable – they adjust network terms and reimbursement schedules state by state without changing the underlying economics of the model in any fundamental way.
The specialty drug market is not going to shrink. Pipeline data from major pharmaceutical manufacturers shows the next decade of drug approvals is weighted heavily toward biologics, cell therapies, and other specialty categories. That means the reimbursement fight happening now will only intensify as the volume of high-cost prescriptions increases – and as PBMs, manufacturers, and pharmacies battle over who absorbs the cost of delivering them profitably.
